Results 61 to 70 of about 1,917,601 (292)

Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma. [PDF]

Front Immunol
Background Blood eosinophil count is usually employed as a predictive and response biomarker for mepolizumab treatment. However, its decrease is not always associated with an improvement in asthma symptoms.
Miguéns-Suárez P, Martelo-Vidal L, Vázquez-Mera S, Blanco-Aparicio M, Calvo-Álvarez U, González-Fernández C, Mosteiro-Añón M, Corbacho-Abelaira D, Hermida-Valverde T, Calvo-Henríquez C, Nieto-Fontarigo JJ, Salgado FJ, González-Barcala FJ.   +12 more
europepmc   +3 more sources

Problematic severe asthma in children, not one problem but many: a GA(2)LEN initiative

, 2010
Although most children with asthma are easy to treat with low doses of safe medications, many remain symptomatic despite every therapeutic effort.
Hedlin G, Lødrup Carlsen K, PERONI, Diego, Problematic Severe Asthma in Childhood Initiative group, Bush A   +4 more
core   +1 more source

Omalizumab: clinical use for the management of asthma [PDF]

, 2012
Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment option for patients with moderate to severe allergic asthma whose asthma is poorly controlled with inhaled corticosteroids and inhaled long-acting ß2 agonist ...
Rekha Chaudhuri, Neil C. Thomson, Thomson, N.C., Chaudhuri, R.   +3 more
core   +1 more source

Poly(I:C)‐Activated Nasal Fibroblasts Promote Eosinophil Recruitment in CRSwNP

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by persistent mucosal inflammation and eosinophilic infiltration. Although epithelial and immune cells have been widely studied, the role of nasal fibroblasts in innate immune activation and eosinophil recruitment remains unclear.
Chaewon Shin, An‐Gi Kim, Byeong Min Yu, Woo‐Keun Kwon, Min‐Ho Hwang, Joo‐Hoo Park   +5 more
wiley   +1 more source

Assessing the Mucosal Inflammatory Endotype of Obesity in Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory syndrome of the paranasal sinuses that is defined phenotypically as either with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP). More recently, inflammatory markers have been used to cluster patients into putative endotypes that are presumed to have a common ...
Jeffanie W. Gayoso, Li‐Ching Huang, Quanhu Sheng, Daniel Lofgren, Ping Li, Katherine Cahill, Mason Krysinski, Rakesh K. Chandra, Justin H. Turner, Naweed Chowdhury   +9 more
wiley   +1 more source

Primary care of asthma: new options for severe eosinophilic asthma [PDF]

Current Medical Research and Opinion, 2019
Objective: Asthma is a common heterogeneous disease characterized by airway inflammation and bronchoconstriction. Current treatment guidelines provide recommendations for categorizing disease severity, asthma control and management. This paper reviews asthma assessment in primary care and describes the pathophysiology, clinical characteristics and new ...
Neil S, Skolnik, Sean P, Carnahan
openaire   +2 more sources

The Mixed Neutrophilic–Eosinophilic Endotype of CRSwNP Blunts Postsurgical Improvement as Determined by the Completeness of Surgery Index

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background The Completeness of Surgery Index (CoSI) is a novel metric for assessing surgical quality in chronic rhinosinusitis with nasal polyps (CRSwNP). Structured histopathology (SHP) is helpful for characterizing drivers of inflammation. Integrating these two tools to identify patients at higher risk for surgically recalcitrant disease has
Vidit M. Talati, Kerol Faltas, Michael R. Xiang, Randy Bach, Spencer L. Yueh, Margaret B. Mitchell, Alan D. Workman, Michael A. Kohanski, Nithin D. Adappa, Jennifer E. Douglas, Noam A. Cohen, John V. Bosso, James N. Palmer   +12 more
wiley   +1 more source

Role of biologics in severe eosinophilic asthma – focus on reslizumab

, 2016
Girolamo Pelaia,1 Alessandro Vatrella,2 Maria Teresa Busceti,1 Luca Gallelli,3 Mariaimmacolata Preianò,3 Nicola Lombardo,1 Rosa Terracciano,3 Rosario Maselli1 1Department of Medical and Surgical Sciences, Section of Respiratory Diseases ...
Vatrella A, Gallelli L, Busceti MT, Maselli R, Terracciano R, Lombardo N, Preianò M, Pelaia G   +7 more
core   +1 more source

A community study of factors related to poorly controlled asthma among Brazilian urban children. [PDF]

, 2012
BACKGROUND: Asthma constitutes a serious public health problem in many regions of the world, including the city of Salvador, State of Bahia-Brazil. The purpose of this study was to analyse the factors associated with poor asthma control.
Cruz, Alvaro A., Dias Karen Conceição, Alcântara-Neves Neuza M., Barreto Maurício L., da Cunha, Sergio S, Dias, Karen Conceição, Amorim, Leila D., de Magalhães Simões, Silvia, Cruz Álvaro A., Amorim Leila D., Amorim, Leila D, Karen Conceição Dias, Barreto, Maurício L, Alcântara-Neves, Neuza M, Cunha, Sergio S. da, Barreto, Mauricio L., Maurício L Barreto, Simões Silvia de Magalhães, Rodrigues Laura C., Álvaro A Cruz, Silvia de Magalhães Simões, Sergio S da Cunha, Leila D Amorim, Laura C Rodrigues, Alcântara, Neuza Maria Neves, Simões, Silvia de Magalhães, Cruz, Álvaro A, da Cunha Sergio S., Rodrigues, Laura C., Rodrigues, Laura C, Neuza M Alcântara-Neves   +30 more
core   +1 more source

Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged <12 years with atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Aim For children with atopic dermatitis (AD), dupilumab is available as a prefilled syringe (PFS) from the age of 6 months and as a prefilled pen (PFP) for patients aged ≥2 years, in 200‐ and 300‐mg devices. This substudy of an ongoing open‐label extension study evaluated the pharmacokinetics, efficacy and safety of switching from a dupilumab PFS ...
Amy S. Paller, Elaine C. Siegfried, Ashish Bansal, Jing Xiao, Faisal A. Khokhar, Michael Van Spall, Xia Liu, Christine Xu, Ariane Dubost‐Brama, Matthew P. Kosloski   +9 more
wiley   +1 more source